title: Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
abstract: OBJECTIVE
  We analyzed in a retrospective analysis whether adjuvant chemotherapy with mitomycin (MMC) alone or with Tegafur (TG) is associated with long-term survival benefit in resected gastric cancer. Other prognostic factors are compared.
  
  
  METHODS
  From 1977 to 1998, 314 consecutive totally resected gastric adenocarcinoma patients have been included in a survival study. In 151 patients no adjuvant therapy was given. In 163 patients, four courses of adjuvant chemotherapy was given, 109 of them with MMC, 10-20 mg/m(2) i.v. every 6 weeks and the other 54 with MMC plus TG, 500 mg/m(2) p.o. day for 42 consecutive days. Univariate and multivariate survival analyses were performed.
  
  
  RESULTS
  Survival benefit was seen in patients who had received adjuvant chemotherapy compared with the controls (52% vs. 30% alive at the end of the study, relative risk = 0.46, 95% CI: 0.33-0.62, P < 0.0001), women (52% vs. 35%, RR = 0.83, 95% CI: 0.71-0.98, P = 0.0342) and increment of staging IB, II, IIIA, or IIIB (80, 56, 24 vs. 13%, respectively, RR = 1.83, 95% CI: 1.42-2.35, P < 0.0001). Better prognosis of node-negative patients was observed only in univariate analysis.
  
  
  CONCLUSIONS
  After curative surgery, adjuvant chemotherapy with mitomycin C, both alone or combined with Tegafur, improved the long-term cure rate over no postoperative chemotherapy in locally advanced gastric cancer patients. This benefit was not influenced by other prognostic factors.
authors.affiliation: Medical Oncology Department, Hospital Clinic of Barcelona Institut Clinic de Malaties Hemato-Oncologiques, University of Barcelona and Hospital De Bellvitge, L'Hospitalet, Barcelona, Spain. jjgrau@medicina.ub.es
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Grau
authors.forename: Marta
authors.initials: M
authors.lastname: Martín
authors.forename: José
authors.initials: J
authors.lastname: Fuster
authors.forename: Manuel
authors.initials: M
authors.lastname: Pera
authors.forename: Juan C
authors.initials: JC
authors.lastname: García-Valdecasas
authors.forename: Josep A
authors.initials: JA
authors.lastname: Bombí
authors.forename: José M
authors.initials: JM
authors.lastname: Bordas
authors.forename: Felipe
authors.initials: F
authors.lastname: Alcobendas
authors.forename: Luis
authors.initials: L
authors.lastname: Grande
authors.forename: Jordi
authors.initials: J
authors.lastname: Estapé
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D016685:Mitomycin